|
|
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial
Arnaud Pigneux
,
Marie Béné
,
Louis-Rachid Salmi
,
Pierre-Yves Dumas
,
Jacques Delaunay
et al.
Journal articles
hal-02874606v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group
Thorsten Braun
,
Sophie Cereja
,
Sylvie Chevret
,
Emmanuel Raffoux
,
Marie Beaumont
et al.
Journal articles
hal-01237097v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
Lionel Adès
,
Xavier Thomas
,
Agnes Guerci Bresler
,
Emmanuel Raffoux
,
Olivier Spertini
et al.
Journal articles
hal-02123075v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study
Arnaud Pigneux
,
Marie C Béné
,
Philippe Guardiola
,
Christian C Recher
,
Jean-Francois Hamel
et al.
Journal articles
inserm-01480651v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group
Lionel Adès
,
Xavier Thomas
,
Agnes Cuerci-Bres
,
Raffoux Emmanuel
,
Olivier Spertini
et al.
Blood, 2015, 126 (23), pp.451
Journal articles
hal-01300812v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier
,
Jean-Francois Hamel
,
Jacques Delaunay
,
Eric Delabesse
,
Pierre-Yves Dumas
et al.
Journal articles
hal-03604930v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
Arnaud Pigneux
,
Christian Récher
,
Marie C. Bene
,
Julien Asselineau
,
Ariane C. Mineur
et al.
Blood, 2015, 126 (23)
Journal articles
hal-01295674v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|